KR102649635B1 - Oral composition comprising policresulen - Google Patents
Oral composition comprising policresulen Download PDFInfo
- Publication number
- KR102649635B1 KR102649635B1 KR1020160140169A KR20160140169A KR102649635B1 KR 102649635 B1 KR102649635 B1 KR 102649635B1 KR 1020160140169 A KR1020160140169 A KR 1020160140169A KR 20160140169 A KR20160140169 A KR 20160140169A KR 102649635 B1 KR102649635 B1 KR 102649635B1
- Authority
- KR
- South Korea
- Prior art keywords
- oral
- sodium
- composition
- polycrezulene
- potassium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 229920001607 Policresulen Polymers 0.000 title claims description 5
- ACZKMKGNTMOPBD-UHFFFAOYSA-N policresulen Chemical compound CC1=CC(O)=C(S(O)(=O)=O)C=C1CC1=CC(S(O)(=O)=O)=C(O)C(CC=2C(=CC(O)=C(C=2)S(O)(=O)=O)C)=C1C ACZKMKGNTMOPBD-UHFFFAOYSA-N 0.000 title claims description 4
- 229960002954 policresulen Drugs 0.000 title claims description 4
- 230000000694 effects Effects 0.000 claims abstract description 33
- 238000001179 sorption measurement Methods 0.000 claims abstract description 12
- 230000014759 maintenance of location Effects 0.000 claims abstract description 7
- 235000002639 sodium chloride Nutrition 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 32
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 21
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 21
- 241001330002 Bambuseae Species 0.000 claims description 21
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 21
- 239000011425 bamboo Substances 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 3
- 235000019801 trisodium phosphate Nutrition 0.000 claims description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 2
- 235000019800 disodium phosphate Nutrition 0.000 claims 2
- ATGAWOHQWWULNK-UHFFFAOYSA-I pentapotassium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [K+].[K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O ATGAWOHQWWULNK-UHFFFAOYSA-I 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 abstract description 14
- 230000007505 plaque formation Effects 0.000 abstract description 6
- 208000007565 gingivitis Diseases 0.000 abstract description 5
- 201000001245 periodontitis Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 239000000606 toothpaste Substances 0.000 description 26
- 229940034610 toothpaste Drugs 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- -1 sulfate compound Chemical class 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000004088 foaming agent Substances 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000001680 brushing effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004267 EU approved acidity regulator Substances 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000059266 Piper nigrescens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y10S514/8995—
-
- Y10S514/90—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 폴리크레줄렌을 함유하는 구강용 조성물에 관한 것으로서, 구강조직수렴제를 이용하여 폴리크레줄렌의 구강 내 잔류 및/또는 흡착을 높이고, 폴리크레줄렌의 효과를 향상시키는 것을 특징으로 한다. 따라서 본 발명에 따른 조성물은 치태형성 방지 효과, 및 치주염, 치은염의 염증 완화 효과가 우수하다. The present invention relates to an oral composition containing polycresulene, which uses an oral tissue astringent to increase the retention and/or adsorption of polycresulene in the oral cavity and improve the effect of polycresulene. Therefore, the composition according to the present invention is excellent in preventing plaque formation and alleviating inflammation in periodontitis and gingivitis.
Description
본 발명은 폴리크레줄렌을 포함하는 구강용 조성물에 관한 것이다. 보다 구체적으로 폴리크레줄렌의 치태형성 방지 효과, 및 치주염과 치은염의 완화 효과가 더욱 개선된 구강용, 특히 구강 위생 증진용 조성물에 관한 것이다.The present invention relates to an oral composition containing polycrezulene. More specifically, it relates to a composition for oral use, particularly for improving oral hygiene, in which polycrezulene has further improved effects of preventing plaque formation and alleviating periodontitis and gingivitis.
구강 내에서 구강균에 의해 형성되는 프라그는 충치, 치은염 등 구강 관련 질환의 1차적 원인이라 할 수 있다. Plaque formed by oral bacteria in the oral cavity can be said to be the primary cause of oral diseases such as cavities and gingivitis.
대한민국 공개특허공보 10-2015-0066756호에서는 폴리크레줄렌이 포함된 바이오필름 형성 억제용 조성물을 통해 폴리크레줄렌을 구강 내에 적용함으로써 생물막 또는 균막이라 불리는 바이오필름의 형성을 억제할 수 있고, 이를 통하여 정상적인 세균의 생태계를 파괴하지 않고도 구강 내에서 프라그 형성을 억제할 수 있음을 개시하고 있다.In Korean Patent Publication No. 10-2015-0066756, the formation of a biofilm called a biofilm or biofilm can be suppressed by applying polycrezulene into the oral cavity through a composition for inhibiting biofilm formation containing polycrezulene, and through this, It is disclosed that plaque formation in the oral cavity can be suppressed without destroying the normal bacterial ecosystem.
그러나, 본 발명자들의 연구 결과 폴리크레줄렌이 함유된 구강용 조성물의 경우 그 효과가 오랫동안 지속되지 않음이 밝혀졌고, 따라서 이러한 효과의 지속을 위한 연구가 필요하게 되었다. However, as a result of the present inventors' research, it was found that the effect of oral compositions containing polycresulene did not last for a long time, and therefore, research was needed to maintain this effect.
따라서 본 발명이 해결하고자 하는 과제는 효과의 지속시간이 늘어나거나(늘어나고) 효과가 향상된 폴리크레줄렌 함유 구강용 조성물, 특히 구강 위생용 조성물을 제공하는 것이다.Therefore, the problem to be solved by the present invention is to provide an oral composition containing polycrezulene, especially an oral hygiene composition, with a longer duration of effect or improved effect.
본 발명이 해결하고자 하는 다른 과제는 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시키기 위한 방법을 제공하는 것이다. Another problem to be solved by the present invention is to provide a method for increasing the duration of the effect of polycresulene or improving the effect of polycresulene.
본 발명이 해결하고자 하는 또 다른 과제는 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시킬 수 있는 조성물 및/또는 이러한 조성물을 포함하는 키트를 제공하는 것이다. Another problem to be solved by the present invention is to provide a composition that can extend the duration of the effect of polycresulene or improve the effect of polycresulene and/or a kit containing such a composition.
상기 과제를 해결하기 위하여, 본 발명은 구강조직수렴제를 이용하여 폴리크레줄렌(policresulen)의 효과 지속시간을 늘리거나(늘리고) 효과를 향상시킬 수 있다는 기술사상을 제공한다.In order to solve the above problems, the present invention provides the technical idea that the duration of effect of policresulen can be increased or the effect can be improved by using an oral tissue astringent.
먼저 본 발명자들의 연구 결과 구강 내 환경의 특성상 수용성 물질인 폴리크레줄렌이 구강 내에서 오래 머무르기 어려워 폴리크레줄렌이 구강 내에서 지속적으로 효과를 발휘하기 어렵다는 점을 확인하였고, 따라서 구강 점막 또는 잇몸에서 잔류하면서 폴리크레줄렌이 약리작용을 지속적으로 유지할 수 있도록 하는 기술을 필요로 하게 되었다. 본 발명자들은 상기와 같은 종래 기술에서의 문제점을 해결하기 위해 다양한 연구를 수행하던 중 폴리크레줄렌을 함유하는 조성물에 구강조직수렴제를 포함시킬 경우 폴리크레줄렌의 구강 내 흡착을 향상시키고, 지속적으로 바이오필름 생성을 억제하는 우수한 효과가 있음을 확인하여 본 발명을 완성하게 되었다. 다만, 본 발명은 이러한 기전적 추측에 한정되는 것은 아니다. First, as a result of the present inventors' research, it was confirmed that it is difficult for polycrezulene, a water-soluble substance, to remain in the oral cavity for a long time due to the characteristics of the oral environment, making it difficult for polycrezulene to continuously exert its effect in the oral cavity. Therefore, it remains in the oral mucosa or gums. Meanwhile, a technology was needed to enable polycrezulene to continuously maintain its pharmacological action. While carrying out various studies to solve the problems in the prior art as described above, the present inventors found that when an oral tissue astringent was included in a composition containing polycrezulene, the oral adsorption of polycrezulene was improved, and the oral bio-absorption was continuously improved. The present invention was completed by confirming that it had an excellent effect in suppressing film formation. However, the present invention is not limited to this mechanistic speculation.
따라서 본 발명은 (a) 폴리크레줄렌(policresulen) 및 (b) 구강조직수렴제를 포함하는 구강용 조성물, 특히 구강 위생 증진용 조성물을 제공한다.Accordingly, the present invention provides an oral composition, particularly a composition for improving oral hygiene, containing (a) polycresulen and (b) an oral tissue astringent.
본 발명은 또한 폴리크레줄렌을 함유하는 구강용 조성물에 있어서, 폴리크레줄렌의 효과를 높이기 위한 용도로 구강조직수렴제를 포함하는 것을 특징으로 하는 구강용, 특히 구강 위생 증진용 조성물을 제공한다.The present invention also provides an oral composition containing polycrezulene, particularly a composition for improving oral hygiene, which includes an oral tissue astringent for the purpose of enhancing the effect of polycrezulene.
본 발명은 또한 구강조직수렴제를 폴리크레줄렌의 적용과 동시에 또는 폴리크레줄렌의 적용 전에 구강 내에 적용하는 것을 특징으로 하는 폴리크레줄렌의 효과를 높이기 위한 방법을 제공한다. 이러한 방법을 통해 구강 내 위생을 더욱 증진할 수 있다. The present invention also provides a method for enhancing the effect of polycresulene, characterized in that an oral tissue astringent is applied intraorally simultaneously with or before the application of polycresulene. Through these methods, oral hygiene can be further improved.
본 발명은 또한 (a) 폴리크레줄렌을 함유하는 조성물, 및 (b) 상기 폴리크레줄렌의 효과를 높이기 위한 용도의 구강조직수렴제를 포함하는 조성물을 포함하는 구강용 키트를 제공한다.The present invention also provides an oral kit comprising (a) a composition containing polycrezulene, and (b) a composition containing an oral tissue astringent for enhancing the effect of polycresulene.
본 발명은 또한 구강조직수렴제를 유효성분으로 포함하는, 폴리크레줄렌의 효과 증진용 조성물을 제공한다.The present invention also provides a composition for enhancing the effect of polycrezulene, which includes an oral tissue astringent as an active ingredient.
본 발명에서 '구강용 조성물' 또는 '구강 위생용 조성물'은 바이오필름의 형성 억제를 통하여 치태형성 방지 및/또는 구강 위생 증진 및/또는 치주염, 치은염과 같은 구강 질환의 예방 및/또는 치료 효과를 갖는 구강에의 적용을 위한 조성물을 의미할 수 있으며, 폴리크레줄렌을 효력증진물질인 구강조직수렴제를 함께 포함함으로써 폴리크레줄렌의 구강 내 잔류 및/또는 흡착이 높아져서 보다 우수한 바이오필름형성 억제를 통하여 상기 목적하는 효과를 더욱 우수하게 발휘할 수 있다.In the present invention, the 'oral composition' or 'oral hygiene composition' has the effect of preventing plaque formation and/or improving oral hygiene and/or preventing and/or treating oral diseases such as periodontitis and gingivitis by inhibiting the formation of biofilm. It may refer to a composition for application to the oral cavity, and by including polycrezulene together with an oral tissue astringent, which is an efficacy enhancing substance, the retention and/or adsorption of polycrezulene in the oral cavity is increased, resulting in better inhibition of biofilm formation. The desired effect can be achieved more excellently.
본 발명에 사용되는 폴리크레줄렌(Policresulene)은 알보칠(Albothyl) 또는 폴리렌(Polilen)으로 불리기도 하며, 하기 화학식 1의 구조를 가지며, 화학식은 (C9H8O4S)n과 같다. Policresulene used in the present invention is also called Albothyl or Polilen, and has the structure of the following formula 1, and the chemical formula is (C 9 H 8 O 4 S) n . .
바람직하게, 상기 화학식 1에서 n은 1 내지 3이며, 더욱 바람직하게 n은 3이다.Preferably, in Formula 1, n is 1 to 3, and more preferably, n is 3.
본 발명의 폴리크레줄렌은 물에 잘 녹기 때문에 물이 과량 함유되어 있는 치약과 같은 구강용 조성물 내에 석출되지 않고 용해되어 존재하게 된다.Since polycrezulene of the present invention is highly soluble in water, it exists dissolved rather than precipitated in oral compositions such as toothpaste containing excessive water.
본 발명에 있어 상기 구강조직수렴제를 폴리크레줄렌의 잔류 및/또는 흡착을 높이는 역할을 함은 분명하나, 이러한 역할 이외에 다른 추가적인 역할을 할 수 있으며, 본 발명은 구강조직수렴제가 작용하는 폴리크레줄렌의 잔류 및/또는 흡착 증진이라는 특별한 이론적 기전에 한정되는 것은 아니다. In the present invention, it is clear that the oral tissue astringent serves to increase the retention and/or adsorption of polycrezulene, but it may play other additional roles in addition to this role, and the present invention provides polycrezulene as an oral tissue astringent. It is not limited to a particular theoretical mechanism of retention and/or adsorption enhancement.
본 발명의 구강조직수렴제는 나트륨, 칼륨, 칼슘, 및 마그네슘과 같이 양이온을 함유한 할로겐족화합물, 설페이트 화합물, 카보네이트 화합물, 인산염화합물 또는 이의 혼합물들이 사용될 수 있다. The oral tissue astringent of the present invention may be a halogen compound, a sulfate compound, a carbonate compound, a phosphate compound, or a mixture thereof containing cations such as sodium, potassium, calcium, and magnesium.
구체적으로, 상기 구강조직수렴제는 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘, 황산나트륨, 황산칼륨, 탄산수소나트륨, 탄산나트륨, 제1인산칼륨, 제2인산칼륨, 제3인산칼륨, 제1인산나트륨, 제2인산나트륨, 제3인산나트륨, 및 사카린나트륨으로 이루어진 군으로부터 선택된 1종 이상일 수 있다. Specifically, the oral tissue astringent is sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium sulfate, potassium sulfate, sodium bicarbonate, sodium carbonate, potassium phosphate monobasic, potassium phosphate dibasic, potassium phosphate tribasic, sodium phosphate monobasic, and potassium phosphate monobasic. It may be one or more selected from the group consisting of sodium phosphate, sodium phosphate tribasic, and sodium saccharin.
상기 염화나트륨은 염화나트륨을 포함하는 소금의 형태로 포함될 수 있고, 예컨대, 죽염, 자죽염, 천일염, 정제소금, 제제소금, 또는 약전소금 등의 형태로 포함될 수 있으며, 바람직하게는 죽염의 형태로 포함될 수 있다. The sodium chloride may be included in the form of salt containing sodium chloride, for example, bamboo salt, bamboo salt, sun-dried salt, refined salt, formulation salt, or pharmacopoeial salt, etc., and preferably may be contained in the form of bamboo salt. there is.
여러 구강조직수렴제들 중에서 특히 죽염의 형태가 실제 사용시 세정감, 깔끔함의 지속, 향미, 전반적인 만족도 등의 측면에서 더욱 바람직하다.Among various oral tissue astringents, the form of bamboo salt is especially preferable in terms of cleansing feeling, lasting cleanliness, flavor, and overall satisfaction during actual use.
본 발명에서 사용하는 염화나트륨 중 죽염은 대나무를 사용한 소금의 총칭으로, 예컨대, 대한민국 특허등록 제85705호에서 언급한 대나무와 소금을 사용하여 화법(火法)을 통해 합성한 죽염이고, 이는 세포를 생성시키는 세포 생산작용을 하는 대나무와 살균 및 부패를 방지하는 소금을 소성로에서 고열로 여러 번 반복 처리하여 소금을 용융시키고, 굳히는 방법으로 죽염을 만들고 있다. 이렇게 제조된 죽염은 나트륨 이외에도 칼륨, 칼슘, 마그네슘, 철 등의 미네랄 성분들이 많이 함유되어 있다. 자죽염의 경우에도 죽염과 유사한 함량의 미네랄 및 이온 성분을 함유하고 있다. 죽염 또는 자죽염에 함유되어 있는 여러 종류의 미네랄 성분과 염화나트륨 성분에 의하여 양치 시 구강 점막의 수렴작용이 특히 탁월하다. 수렴이 발생하면서 팽창되어 있는 세포들이 수축되게 되고 이때 구강 점막에 있던 폴리크레줄렌이 구강 조직에 수렴하게 되며 이로써 잔류하는 폴리크레줄렌이 지속적으로 약효성을 발휘하게 되는 것으로 추측된다. 다만, 본 발명은 이러한 이론적 기전에 한정되는 것은 아니다.Among the sodium chlorides used in the present invention, bamboo salt is a general term for salt using bamboo. For example, it is bamboo salt synthesized through a fire method using bamboo and salt mentioned in Korean Patent Registration No. 85705, which produces cells. Shiki makes bamboo salt by repeatedly processing bamboo, which produces cells, and salt, which sterilizes and prevents decay, at high heat in a kiln to melt and solidify the salt. In addition to sodium, bamboo salt manufactured in this way contains a lot of minerals such as potassium, calcium, magnesium, and iron. In the case of bamboo salt, it contains similar amounts of minerals and ions as bamboo salt. The various mineral components and sodium chloride components contained in bamboo salt or bamboo salt have an especially excellent astringent effect on the oral mucosa when brushing teeth. As convergence occurs, the swollen cells contract, and at this time, polycrezulene in the oral mucosa converges to oral tissue, and it is presumed that the remaining polycrezulene continues to exert medicinal efficacy. However, the present invention is not limited to this theoretical mechanism.
본 발명에 따른 구강용 조성물 또는 구강 내 폴리크레줄렌 잔류 또는 흡착 증진용 조성물에 있어 폴리크레줄렌의 함량은 본 발명의 여러 목적상 조성물 총 중량 대비 0.0005 내지 2 중량%가 바람직하며, 0.0001 내지 1 중량%가 보다 바람직하고, 0.001 내지 0.1 중량%가 더욱 더 바람직하다. 또한 본 발명에 따른 조성물에 있어 구강조직수렴제의 함량은 본 발명의 여러 목적상 0.1 내지 5 중량%가 바람직하며, 0.2 내지 4 중량%가 더욱 바람직하고, 0.3 내지 3 중량%가 더욱 더 바람직하다. In the oral composition according to the present invention or the composition for promoting the retention or adsorption of polycrezulene in the oral cavity, the content of polycrezulene is preferably 0.0005 to 2% by weight relative to the total weight of the composition for various purposes of the present invention, and 0.0001 to 1% by weight. % is more preferred, and 0.001 to 0.1% by weight is even more preferred. In addition, the content of the oral tissue astringent in the composition according to the present invention is preferably 0.1 to 5% by weight, more preferably 0.2 to 4% by weight, and even more preferably 0.3 to 3% by weight for various purposes of the present invention.
상기 폴리크레줄렌의 함량은 조성물 총 중량 대비 0.0005 중량% 미만일 때는 바이오필름 생성 억제 효과가 미미하여 본 발명의 실질적 목적을 달성하기 쉽지 않았으며, 2 중량% 초과일 때는 자극 및 외과적 상처를 일으킬 수 있다는 문제점이 있다.When the content of polycrezulene is less than 0.0005% by weight relative to the total weight of the composition, the effect of inhibiting biofilm formation is minimal, making it difficult to achieve the practical purpose of the present invention, and when it is more than 2% by weight, it may cause irritation and surgical wounds. There is a problem.
상기 구강조직수렴제는 폴리크레줄렌의 흡착 및 잔류 효과의 상승 등 본 발명의 목적을 위해 첨가하는 것으로, 그 함량이 조성물 총 중량 대비 0.1 중량% 미만이면 구강 내 흡착 및 잔류 효과가 미약하게 되고, 5 중량%를 초과하면 함량 증가에 따른 효과가 미미할 뿐만 아니라 염의 과량 첨가로 인해 짠맛, 비린맛, 떫은 맛 등이 강하게 나타날 수 있다. 본 발명자들이 남녀 10여명을 대상으로 수행한 관능평가 결과 5 중량%를 초과하는 경우 소비자 선호도가 매우 떨어지는 결과를 나타내었다. The oral tissue astringent is added for the purpose of the present invention, such as increasing the adsorption and residual effect of polycrezulene. If the content is less than 0.1% by weight based on the total weight of the composition, the oral adsorption and residual effect are weak, 5 If the weight percent is exceeded, not only will the effect of increasing the content be minimal, but salty, fishy, and astringent tastes may appear due to excessive addition of salt. As a result of a sensory evaluation conducted by the present inventors on about 10 men and women, consumer preference was very low when the amount exceeded 5% by weight.
본 발명의 조성물은 치약, 구강 청정제, 양치액, 구강 스프레이, 껌, 구강 연고, 구강용 패취제 등 다양한 형태로 제공될 수 있다. 상기 조성물의 형태, 종류 및 사용 목적에 따라 통상적으로 연마제, 습윤제, 결합제, 기포제, 감미제, 방부제, 약효제, 향료, 산성도 조절제, 증백제 등을 적당량 배합하여 사용할 수 있다. 즉, 본 발명에 따른 조성물은 앞서 언급된 성분들 이외에 또한 구강용 조성물에 적절한 제형화, 제형 안정성, 소망하는 효과의 증진, 사용 기호도 증진 등을 위하여, 연마제, 습윤제, 결합제, 기포제, 감미제, 약효제, 향료, 정제수 등으로 이루어진 군에서 선택된 1종 이상의 첨가제를 추가로 함유할 수 있다.The composition of the present invention may be provided in various forms such as toothpaste, mouthwash, mouthwash, oral spray, gum, oral ointment, and oral patch. Depending on the form, type, and purpose of use of the composition, an appropriate amount of abrasives, wetting agents, binders, foaming agents, sweeteners, preservatives, medicinal agents, fragrances, acidity regulators, whitening agents, etc. can be used. That is, in addition to the ingredients mentioned above, the composition according to the present invention also contains an abrasive, a wetting agent, a binder, a foaming agent, a sweetener, and medicinal properties in order to formulate an oral composition appropriately, formulate stability, enhance the desired effect, and enhance the preference for use. It may additionally contain one or more additives selected from the group consisting of agents, fragrances, purified water, etc.
본 발명의 구강 위생 증진용 조성물 또는 구강 내 폴리크레줄렌 잔류/흡착 증진용 조성물을 포함하는 제형이 치약 조성물인 경우, 연마제, 습윤제, 결합제, 기포제, 감미제, 약효제, 향료, 산성도 조절제 및 증백제로 이루어진 군으로부터 선택된 1종 이상의 첨가제를 더욱 포함할 수 있다.When the formulation containing the composition for improving oral hygiene of the present invention or the composition for improving retention/adsorption of polycrezulene in the oral cavity is a toothpaste composition, abrasives, wetting agents, binders, foaming agents, sweeteners, medicinal agents, flavorings, acidity regulators and whitening agents It may further include one or more additives selected from the group consisting of.
상기 연마제는 인산일수소칼슘, 침강실리카, 탄산칼슘, 함수알루미나, 카오린 및 중조로 이루어진 군으로부터 선택된 1종 이상, 바람직하게는 인산일수소칼슘 및/또는 침강실리카이고, 조성물 총 중량 대비 5 내지 50 중량%로 사용할 수 있다.The abrasive is at least one selected from the group consisting of calcium monohydrogen phosphate, precipitated silica, calcium carbonate, hydrous alumina, kaolin, and sodium bicarbonate, preferably calcium monohydrogen phosphate and/or precipitated silica, and is used in an amount of 5 to 50% based on the total weight of the composition. It can be used as weight percent.
상기 습윤제로는 글리세린, 소르비톨, 비결정성 소르비톨액, 프로필렌글리콜, 폴리에틸렌 글리콜 및 자일리톨로 이루어진 군으로부터 선택된 1 종 이상, 바람직하게는 소르비톨액이고, 예를 들어, 조성물 총 중량 대비 20 내지 60 중량%로 사용할 수 있다.The humectant is at least one selected from the group consisting of glycerin, sorbitol, amorphous sorbitol solution, propylene glycol, polyethylene glycol, and xylitol, preferably sorbitol solution, for example, 20 to 60% by weight based on the total weight of the composition. You can use it.
상기 결합제로는 카르복시메틸셀룰로오스나트륨, 카라기난, 잔탄검, 히드록시에틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 구아검, 젤란검, 카르보머, 펙틴, 폴리비닐피롤리돈, 카르복시비닐폴리며, 알긴산나트륨 및 라포나이트로 이루어진 군으로부터 선택된 1종 이상, 바람직하게는 카르복시메틸셀룰로오스나트륨이고, 예를 들어, 조성물 총 중량 대비 0.5 내지 2 중량%로 사용할 수 있다.The binders include sodium carboxymethylcellulose, carrageenan, xanthan gum, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, guar gum, gellan gum, carbomer, pectin, polyvinylpyrrolidone, carboxyvinylpoly. and at least one selected from the group consisting of sodium alginate and laponite, preferably sodium carboxymethyl cellulose, and can be used, for example, in an amount of 0.5 to 2% by weight based on the total weight of the composition.
상기 기포제로는 라우릴황산나트륨, 라우릴사르코신산나트륨 등의 음이온계면활성제; 소르비탄 지방산에스테르, 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌/폴리옥시프로필렌계 공중합 물질 등으로 이루어진 비이온계면활성제; 또는 코코아이도프로필베타인 등의 양쪽성 계면활성제로부터 선택된 1종 이상, 바람직하게는 라우릴황산나트륨이고, 조성물 총 중량 대비 0.5 내지 5 중량%로 사용할 수 있다.Examples of the foaming agent include anionic surfactants such as sodium lauryl sulfate and sodium lauryl sarcosinate; Nonionic surfactants made of sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene/polyoxypropylene copolymer, etc.; Or at least one selected from amphoteric surfactants such as cocoaidopropyl betaine, preferably sodium lauryl sulfate, and can be used in an amount of 0.5 to 5% by weight based on the total weight of the composition.
상기 감미제는 수크랄로스, 말티톨, 아스파탐, 에리스리톨 및 감초산으로 이루어진 군으로부터 선택된 1종 또는 2종 이상, 바람직하게는 수크랄로스이고, 조성물 총 중량 대비 0.05 내지 0.3 중량%로 사용할 수 있다.The sweetener is one or two or more selected from the group consisting of sucralose, maltitol, aspartame, erythritol, and licorice acid, preferably sucralose, and can be used in an amount of 0.05 to 0.3% by weight based on the total weight of the composition.
상기 약효제로는 불화나트륨, 불화인산나트륨, 불화제일석, 불화아민, 클로르헥시딘, 아미노카프로산, 글리시리진산디칼륨, 트라넥사민산, 알로토인류, 카프론산류, 폴리인산염류, 효소류 및 생약추출물로 이루어진 군으로부터 선택된 1종 이상, 바람직하게는 불화나트륨이고, 조성물 총 중량 대비 0.1 내지 0.3 중량%로 사용할 수 있다.The medicinal agents include sodium fluoride, sodium fluorophosphate, stannic fluoride, amine fluoride, chlorhexidine, aminocaproic acid, dipotassium glycyrrhizinate, tranexamic acid, allotoin, caproic acid, polyphosphates, enzymes, and herbal extracts. At least one selected from the group consisting of, preferably sodium fluoride, can be used in an amount of 0.1 to 0.3% by weight based on the total weight of the composition.
상기 향료로는 페퍼민트오일, 스피어민트오일 등의 천연 향료와 멘톨, 카르본 등의 합성착향료를 적당량 혼합하여 사용하며, 바람직하게는 이들을 일정 비율 혼합한 향료에 아니스 오일을 적당량 혼합하는 것이 좋다. 향료의 함량은 조성물 총 중량 대비 0.5 내지 3중량%로 사용할 수 있다.The above flavoring agent is used by mixing an appropriate amount of natural flavoring agents such as peppermint oil, spearmint oil, etc., and synthetic flavoring agents such as menthol and carbonate. Preferably, an appropriate amount of anise oil is mixed with the flavoring material mixed in a certain ratio. The content of fragrance can be 0.5 to 3% by weight based on the total weight of the composition.
예컨대, 상기 구강용 위생용 조성물 또는 구강 내 폴리크레줄렌 흡착 증진용 조성물은 조성물 총 중량 대비 폴리크레줄렌 0.0005 내지 2 중량% 및 염화나트륨 0.1 내지 5 중량%를 포함하고, 첨가제로서 연마제 15 내지 60 중량%, 습윤제 20 내지 60 중량%, 결합제 0.5 내지 20 중량%, 기포제 0.5 내지 5 중량%, 감미제 0.05 내지 0.3 중량%, 약효제 0.1 내지 0.3 중량%, 향료 0.5 내지 3 중량% 및 잔량의 정제수를 포함하는 것일 수 있다.For example, the oral hygiene composition or the composition for enhancing the adsorption of polycrezulene in the oral cavity includes 0.0005 to 2% by weight of polycrezulene and 0.1 to 5% by weight of sodium chloride based on the total weight of the composition, and 15 to 60% by weight of an abrasive as an additive. , 20 to 60% by weight of wetting agent, 0.5 to 20% by weight of binder, 0.5 to 5% by weight of foaming agent, 0.05 to 0.3% by weight of sweetener, 0.1 to 0.3% by weight of medicinal agent, 0.5 to 3% by weight of fragrance, and the balance of purified water. It could be.
본 발명은 효과의 지속시간이 늘어나거나(늘어나고) 효과가 향상된 폴리크레줄렌 함유 구강용 조성물, 특히 구강 위생용 조성물을 제공한다. The present invention provides an oral composition, particularly an oral hygiene composition, containing polycrezulene, which has a longer duration of effect or improved effect.
본 발명은 또한 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시키기 위한 방법을 제공한다. The present invention also provides a method for increasing the duration of the effect of polycresulene or improving the effect of polycresulene.
본 발명은 또한 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시킬 수 있는 조성물 및/또는 이러한 조성물을 포함하는 키트를 제공한다. The present invention also provides compositions and/or kits containing such compositions that can extend (increase) the duration of effect of polycresulene or improve the effect of polycresulene.
결과적으로 본 발명에 따른 조성물은 폴리크레줄렌의 구강 내 잔류력을 향상시키고, 치태형성 방지 효과, 및 치주염, 치은염의 염증 완화 효과가 우수하다. As a result, the composition according to the present invention improves the residual power of polycrezulene in the oral cavity, has an excellent effect of preventing plaque formation, and has an effect of alleviating inflammation in periodontitis and gingivitis.
도 1은 실험예 2의 결과물들의 평점에 사용된 플라크 지표(index)를 보여주는 도면이다. 당업계에서 통상적으로 사용되는 "Turesky Modification of Quigley-Hein plaque index"를 사용하였다.
도 2는 본 발명에 따른 일 실시예들인 치약들의 소비자 평가에서 사용한 설문지를 나타낸다.
도 3은 본 발명에 따른 일 실시예들인 치약들의 소비자 평가 결과이다.Figure 1 is a diagram showing the plaque index used to evaluate the results of Experimental Example 2. The “Turesky Modification of Quigley-Hein plaque index” commonly used in the art was used.
Figure 2 shows a questionnaire used in consumer evaluation of toothpastes according to one embodiment of the present invention.
Figure 3 shows the results of consumer evaluation of toothpastes according to one embodiment of the present invention.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, to aid understanding of the present invention, it will be described in detail through examples. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
실시예Example 1 내지 11 및 1 to 11 and 비교예Comparative example 1 내지 3 1 to 3
실시예 1 내지 11 및 비교예 1 내지 3의 치약 조성물은 하기 표 1에 나타낸 성분 및 조성비로 제조하였다. 습윤 성분인 솔르비톨액에 카르복시 메틸셀룰로오스나트륨, 등의 분말 성분을 분산시키고 정제수를 넣은 다음 혼합기에서 1차 혼합하였다. 그 다음에 침강 실리카 등의 연마제와 약효제를 투입하고 혼합하였다.The toothpaste compositions of Examples 1 to 11 and Comparative Examples 1 to 3 were prepared with the ingredients and composition ratios shown in Table 1 below. Powder components such as sodium carboxymethyl cellulose were dispersed in the sorbitol solution, which is a wet component, purified water was added, and then mixed first in a mixer. Next, an abrasive such as precipitated silica and a medicinal agent were added and mixed.
마지막으로 기포제인 라우릴 황산나트륨 및 향료성분을 넣고 진공상태하에서 혼합하여 치약 조성물을 제조하였다.Finally, sodium lauryl sulfate as a foaming agent and flavoring ingredients were added and mixed under vacuum to prepare a toothpaste composition.
(단위: 중량%)division
(Unit: weight%)
(70%)Sorbitol solution
(70%)
실험예 1. 폴리크레줄렌의 검출 유무 측정Experimental Example 1. Measurement of detection of polycrezulene
상기 표 1의 실시예 및 비교예의 조성물을 20~40대 남여 소비자 10명을 대상으로 양치를 1분간 하게 한 후, 타액을 시간 경과에 따라 타액을 채취하여 폴리크레줄렌의 검출 유무를 액체크로마토그래프법을 이용하여 측정하였다.After brushing the teeth of 10 male and female consumers in their 20s to 40s for 1 minute with the compositions of the Examples and Comparative Examples in Table 1 above, saliva was collected over time and the presence or absence of polycresulene was detected using liquid chromatography. It was measured using the method.
측정 결과는 하기 표 2에서 폴리크레줄렌의 검출 또는 불검출(검출(O), 불검출(X))로만 표기하였다.The measurement results are indicated only as detection or non-detection (detection (O), non-detection (X)) of polycrezulene in Table 2 below.
상기 표 2에서 나타나는 바와 같이, 실험결과 실시예에서는 폴리크레줄렌이 양치 후 30분까지 지속적으로 검출되는 것을 확인하였으나, 비교예 2의 치약은 양치 직후에는 검출이 되었으나, 타액에 의한 희석 및 섭취로 인하여 양치 직후인 5분 후에도 검출되지 않는 것이 확인되었다. 즉 구강조직수렴제와 동시에 사용하여 줌으로써 폴리크레줄렌의 잔류력이 현격하게 증가하였음을 확인할 수 있었다.As shown in Table 2, it was confirmed that polycrezulene was continuously detected in the experimental results up to 30 minutes after brushing teeth, but in the toothpaste of Comparative Example 2, it was detected immediately after brushing teeth, but due to dilution and ingestion by saliva. Therefore, it was confirmed that it was not detected even after 5 minutes immediately after brushing teeth. In other words, it was confirmed that the residual power of polycrezulene increased significantly when used simultaneously with an oral tissue astringent.
실험예Experiment example 2. 2. 폴리크레줄렌polycrezulene 및 죽염 함유치약의 and bamboo salt-containing toothpaste 치면세균막형성Tooth surface bacterial film formation 억제 효과 inhibitory effect
<실험 방법><Experiment method>
현존 자연치아 수가 최소 20개 이상인 만 20-65세 성인 남녀를 대상으로 상기 표 1의 실시예 2 및 비교예 1 내지 2를 4주간 사용하게 한 뒤 초기 및 4주 후에 다음 방식으로 치면 세균막 지수를 점수로 평가하였다. 연구 대상자 구강 내 존재하는 20개 이상의 모든 자연치를 대상으로 한 치아를 6개 면(협측-근심, 협측-중앙, 협측-원심, 설측-근심, 설측-중앙, 설측-원심)으로 나누어 평가하였다. 이 때, 고정성 교정 장치가 장착되어 있거나 전체 치면을 수복한 치관은 제외하였다. 치면세균막 형성억제를 평가하기 위한 지수 평가는 치태 염색 시약을 이용하여 치태를 염색한 후, Turesky Modification of Quigley-Hein plaque index (PI)를 도 1 및 다음과 같은 기준에 의하여 1인 검사자가 평점하였다. Adult men and women aged 20 to 65 years old with at least 20 existing natural teeth were asked to use Example 2 and Comparative Examples 1 to 2 in Table 1 for 4 weeks, and then initially and after 4 weeks, the biofilm index was measured in the following manner. It was evaluated by score. All 20 or more natural teeth present in the study subjects' mouths were evaluated by dividing them into 6 planes (buccal-mesial, buccal-central, buccal-distal, lingual-mesial, lingual-central, and lingual-distal). At this time, crowns equipped with fixed orthodontic devices or in which the entire tooth surface was restored were excluded. To evaluate the index to evaluate the inhibition of dental plaque formation, plaque was stained using a plaque staining reagent, and the Turesky Modification of Quigley-Hein plaque index (PI) was evaluated by one examiner based on Figure 1 and the following criteria. .
0점 = 전혀 치태가 없는 경우 0 points = no plaque at all
1점 = 치태가 연결되지 않고 한 개의 섬 형태를 지닐 경우1 point = If the plaque is not connected and forms an island
2점 = 치은변연을 따라 선의 형태로 치태가 있는 경우 2 points = If there is plaque in the form of a line along the gingival margin
3점 = 치경부 1/3 부위에 치태가 있는 경우 3 points = If there is plaque in the cervical 1/3 area
4점 = 치관의 2/3 부위에 치태가 있는 경우 4 points = Plaque on 2/3 of the crown
5점 = 치관 전체를 거의 치태가 덮은 경우 5 points = When plaque covers almost the entire crown
PI = 총 점수의 합 / 검사한 총 치면수 PI = sum of total scores / total number of teeth inspected
<실험 결과><Experiment results>
치태지수 측정결과를 하기 표 3에 나타내었다. 하기 표 3에 나타나는 바와 같이, 치약 사용 4주 후의 결과를 비교하면 비교예 1 치약 사용 후 초기대비 5.6% 증가하였고, 비교예 2 치약에서는 2.7% 감소하였고, 실시예 2 치약에서는 4.6% 감소하였다. 또한 연구대상자 중에서 치약 사용 4주 후 치태 지수가 치약 사용 전과 동일하거나 그보다 감소한 것으로 확인된 효과자율은 비교예 2 치약 사용자의 58%와 실시예 2 치약 사용자의 82%에 해당하는 것으로 확인되었다. 이를 통하여, 폴리크레줄렌 및 죽염을 함유한 구강용 조성물은 다양한 원인(예를 들어, 폴리크레줄렌의 구강 내에서의 흡착 증대)을 통하여 그 기능의 시너지적 증가를 가져옴을 알 수 있다.The plaque index measurement results are shown in Table 3 below. As shown in Table 3 below, when comparing the results after 4 weeks of using toothpaste, the toothpaste in Comparative Example 1 increased by 5.6% compared to the initial period, decreased by 2.7% in the toothpaste in Comparative Example 2, and decreased by 4.6% in the toothpaste in Example 2. In addition, among the study subjects, the effectiveness rate confirmed that the plaque index after 4 weeks of toothpaste use was the same or decreased than before toothpaste use was 58% of the toothpaste users in Comparative Example 2 and 82% of the toothpaste users in Example 2. Through this, it can be seen that the oral composition containing polycresulene and bamboo salt results in a synergistic increase in its function through various causes (for example, increased adsorption of polycresulene in the oral cavity).
평균(표준편차)Baseline
Mean (standard deviation)
평균(표준편차)4 weeks later
Mean (standard deviation)
실험예Experiment example 3. 3. 폴리크레줄렌polycrezulene 및 and 구강조직수렴제Oral tissue astringent 함유 치약의 소비자 평가 Consumer evaluation of toothpaste containing
하기와 같은 방법으로 폴리크레줄렌 및 구강조직수렴제를 함유하는 치약의 소비자 관능 평가를 실시하였다.Consumer sensory evaluation of toothpaste containing polycrezulene and oral tissue astringent was conducted in the following manner.
실험 대상자: 만 20-40대 성인 남녀 자원자 30명을 공개 모집하였다.Experimental subjects: 30 adult male and female volunteers in their 20s to 40s were publicly recruited.
실험방법: 실험 대상자들에게 1주일 주기로 새로운 치약을 지급하여 해당 치약만 사용하게 하면서, 설문조사를 통해 사용감에 대해 평가하게 하였다.Experimental method: Test subjects were given new toothpaste every week and were asked to use only that toothpaste and evaluate their feeling of use through a survey.
실험치약: 상기 표 1의 실시예 2 및 실시예 6 내지 11을 실험치약으로 지급하였다. 모든 조성물은 동일한 향료 및 색상을 적용하여 향료 및 색상에 의한 호불호는 사전에 방지하였다.Experimental toothpaste: Examples 2 and 6 to 11 of Table 1 above were provided as experimental toothpastes. All compositions used the same fragrance and color to prevent likes and dislikes due to fragrance and color.
설문항목: 도 2에 나타난 바와 같은 소비자 평가용 설문지를 이용하여 평가하였다.Survey items: Evaluated using a consumer evaluation questionnaire as shown in Figure 2.
그 결과를 하기 도 3에 나타내었다. 도 3에 나타나는 바와 같이, 소비자 평가 결과는 실시예 2의 조성물이 세정감, 깔끔함의 지속, 향미 및 전반적인 만족도의 항목에서 가장 만족도가 높음을 알 수 있었다.The results are shown in Figure 3 below. As shown in Figure 3, the consumer evaluation results showed that the composition of Example 2 had the highest satisfaction in terms of cleansing feeling, continuation of neatness, flavor, and overall satisfaction.
실험예Experiment example 4. 4. 폴리크레줄렌polycrezulene 및 and 구강조직수렴제Oral tissue astringent 함유 치약의 항균력 평가 Evaluation of antibacterial activity of toothpaste containing
하기와 같은 방법으로 폴리크레줄렌 및 구강조직수렴제를 함유하는 치약의 소비자 관능 평가를 실시하였다.Consumer sensory evaluation of toothpaste containing polycrezulene and oral tissue astringent was conducted in the following manner.
균주: Streptococcus mutans (ATCC 25175), Porphyromonas gingivalis (ATCC 49417), Prevotella nigrescens (ATCC 25261), Fusobacterium nucleatum (ATCC 25586)을 사용하였다. 균주는 Brain Heart Infusion (BHI: Difco, USA) 액체 배지에서 1~2차 계대 배양 후 같은 배지에 접종하여 37℃ 혐기성배양기 (Anaerobic incubator) 에서 72시간 배양 후 사용하였다. 배지는 BHI에 menadion(50ng/ml)과 hemin(4ug/ml)을 첨가하여 사용하였다.Strains: Streptococcus mutans (ATCC 25175), Porphyromonas gingivalis (ATCC 49417), Prevotella nigrescens (ATCC 25261), Fusobacterium nucleatum (ATCC 25586) was used. The strain was subcultured in Brain Heart Infusion (BHI: Difco, USA) liquid medium for the first and second rounds, then inoculated into the same medium and cultured in an anaerobic incubator at 37°C for 72 hours before use. The medium was used by adding menadion (50ng/ml) and hemin (4ug/ml) to BHI.
실험방법: 상기 표 1의 실시예 2 및 실시예 6 내지 11을 BHI 액체배지에 희석하여 최종농도를 10%로 맞추고 3×105 CFU/ml의 세균과 함께 3분간 추가 배양하였다. 이 후 배양액을 순차적으로 희석하여 고체배지에 48시간 추가 배양하여 나타나는 CFU(Colony Forming Unit)를 조사하였다. 모든 실험군은 3회 반복 실험하였다.Experimental method: Examples 2 and 6 to 11 of Table 1 were diluted in BHI liquid medium to adjust the final concentration to 10% and further incubated with 3 × 10 5 CFU/ml of bacteria for 3 minutes. Afterwards, the culture medium was sequentially diluted and cultured on solid medium for an additional 48 hours, and the resulting CFU (Colony Forming Unit) was examined. All experimental groups were repeated three times.
그 결과를 하기 표 4에 나타내었다. 실험에 사용된 구강 내 미생물에 대한 항균력 비교 실험의 결과, 하기 표 4에 나타나는 바와 같이, 실시예 2의 조성물이 가장 항균력이 높음을 알 수 있었다.The results are shown in Table 4 below. As a result of a comparison test of antibacterial activity against oral microorganisms used in the experiment, it was found that the composition of Example 2 had the highest antibacterial activity, as shown in Table 4 below.
Claims (9)
폴리크레줄렌의 효과를 높이기 위한 용도로 구강조직수렴제를 포함하는 것을 특징으로 하는 구강용 조성물.In the oral composition containing policresulen,
An oral composition comprising an oral tissue astringent for enhancing the effect of polycrezulene.
(b) 상기 폴리크레줄렌의 효과를 높이기 위한 용도의 구강조직수렴제를 포함하는 조성물을
포함하는 구강용 키트.(a) a composition containing polycrezulene, and
(b) a composition containing an oral tissue astringent for enhancing the effect of polycrezulene.
Oral kit containing:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160140169A KR102649635B1 (en) | 2016-10-26 | 2016-10-26 | Oral composition comprising policresulen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160140169A KR102649635B1 (en) | 2016-10-26 | 2016-10-26 | Oral composition comprising policresulen |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180045614A KR20180045614A (en) | 2018-05-04 |
KR102649635B1 true KR102649635B1 (en) | 2024-03-19 |
Family
ID=62199921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160140169A KR102649635B1 (en) | 2016-10-26 | 2016-10-26 | Oral composition comprising policresulen |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102649635B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102077807B1 (en) * | 2018-08-29 | 2020-02-17 | 이향선 | Pharmaceutical composition for preventing or treating glioblastoma comprising pyrvinium and policresulen |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010069757A (en) | 2001-05-08 | 2001-07-25 | 류형선 | The new composition of taste masked policresulen solution |
KR20040107974A (en) * | 2003-06-16 | 2004-12-23 | 한국디디에스제약 주식회사 | Oral applicator containing xylitol |
KR102086804B1 (en) | 2013-12-09 | 2020-03-09 | 주식회사 엘지생활건강 | Composition for preventing a biofilm formation |
-
2016
- 2016-10-26 KR KR1020160140169A patent/KR102649635B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
J. of Korean Academy of Oral Health 2015 December 39(4):267-272, 1부.* |
Also Published As
Publication number | Publication date |
---|---|
KR20180045614A (en) | 2018-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6471667B2 (en) | Liquid oral composition | |
TW201534336A (en) | Oral care composition | |
US20200121574A1 (en) | Mouthwash composition | |
KR101636430B1 (en) | Improved anti-inflammatory and germicidal composition for preventing or alleviating periodontal disease | |
KR101449453B1 (en) | Dental composition for a foul smell removal, antiplaque and excellent anti-microbial effect | |
KR101216427B1 (en) | Calendula officinalis dentifrice composition and process for preparing the same | |
WO2005072691A1 (en) | Composition for inhibiting halitosis | |
KR102649635B1 (en) | Oral composition comprising policresulen | |
WO2014036564A1 (en) | Oral care composition for promoting and maintaining oral health and method of forming and using same | |
KR102196459B1 (en) | A toothpaste composition with improved antibacterial performance and a toothpaste comprising the composition | |
KR102509579B1 (en) | Oral composition comprising cassava extract | |
CN111050747B (en) | Dentifrice composition | |
KR102597684B1 (en) | Oral composition comprising amaranth extract | |
KR20170051006A (en) | Oral composition containing both isopropylmethylphenol and oral tissue astringent | |
KR101583758B1 (en) | Toothpaste composition comprising kiyoseki stone | |
KR20160061852A (en) | Oral composition containing both metal chelating agent and isopropylmethylphenol | |
JP6435852B2 (en) | Oral composition and method for preventing discoloration of oral composition | |
CN115177543B (en) | Antibacterial caries preventing composition containing L-lactate, oral care product and preparation method and application thereof | |
KR101344803B1 (en) | Oral care composition comprising extract of machilus thunbergii and sequestering agent | |
KR102550067B1 (en) | Oral Composition having policresulen and fluorine compound | |
JPH10167939A (en) | Composition for oral cavity | |
KR20170037231A (en) | Oral composition comprising purslane extract | |
KR102597685B1 (en) | Oral composition comprising parsley extract | |
KR101583760B1 (en) | Toothpaste composition comprising chondrodite | |
WO2023187028A1 (en) | Mouthwash composition comprising one or more strontium salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |